Since 1981, Repligen has provided novel technologies to inspire advances in modern bioprocessing. Beginning with Protein A ligand development, Repligen has become a leading pure-play bioprocessing tools provider by developing flexible, configurable and high-performing solutions.
In 2010, Repligen entered a period of rapid growth propelled by a combination of R&D innovation and strategic acquisitions. This growth accelerated in 2012 when Repligen made the strategic decision to focus on bioprocessing products and systems. In 2018, Repligen was named one of the Top 100 fastest growing companies in the USA. This growth continues today, driven by the technology leadership of Repligen products, and the company's commitment to always put the customer first.
Repligen was founded in 1981 by two distinguished scientists who pioneered breakthrough advances in science and technology.
Alexander Rich was co-Chair of the Repligen Board of Directors until 2014. He was a Professor at the Massachusetts Institute of Technology since 1958. Considered a founding father of the field of molecular biology, he received the National Medal of Science in 1995. He passed away on April 27, 2015 at the age of 90 years old.
Paul Schimmel is the Ernest and Jean Hahn Professor at The Skaggs Institute for Chemical Biology at The Scripps Research Institute. He was formerly the John D. and Catherine T. MacArthur Professor of Biochemistry and Biophysics in the Department of Biology at the Massachusetts Institute of Technology. His principal scientific contributions include the discovery of “The Second Genetic Code" and expansion of the functional genome.